Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
728 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00426556 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | completed | Phase 1 | 88 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 28, 2015 | clinicaltrials |
| NCT00432302 | Investigation of Mass Balance of the Test Drug and Major Metabolites | completed | Phase 1 | 7 | BayerINDUSTRY | 1 | Dec 14, 2015 | clinicaltrials |
| A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer |
| completed |
| Phase 1 |
| 54 |
| Janssen Research & Development, LLCINDUSTRY |
| 4 |
| Dec 4, 2015 |
| clinicaltrials |
| NCT02507375 | A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 17 | Hoffmann-La RocheINDUSTRY | 3 | Oct 16, 2015 | clinicaltrials |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | AmgenINDUSTRY | 3 | Oct 14, 2015 | clinicaltrials |
| NCT01267084 | A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 1 | Oct 14, 2015 | clinicaltrials |
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | completed | Phase 1 | 103 | AmgenINDUSTRY | 3 | Sep 29, 2015 | clinicaltrials |
| NCT01711398 | Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors(IP N02) | completed | Phase 1 / Phase 2 | 15 | Elro PharmaINDUSTRY | 2 | Feb 12, 2015 | clinicaltrials |
| NCT01386580 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | completed | Phase 1 / Phase 2 | 84 | BBB-Therapeutics B.V.INDUSTRY | 4 | Jan 22, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 | clinicaltrials |
| NCT00823420 | Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential | terminated | Phase 1 | 213 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 5, 2014 | clinicaltrials |
| NCT00822874 | Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential | terminated | Phase 1 | 115 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT01674322 | A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants | completed | Phase 1 | 6 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 5, 2014 | clinicaltrials |
| NCT01834469 | Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients(OV-AP-ICG-IV) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT01993576 | ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.(EC2075) | completed | Phase 1 / Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00841191 | A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | completed | Phase 1 / Phase 2 | 84 | Centocor, Inc.INDUSTRY | 5 | May 14, 2014 | clinicaltrials |
| NCT00705016 | Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)(ADVANTAGE) | completed | Phase 1 / Phase 2 | 184 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 9 | Apr 30, 2014 | clinicaltrials |
| NCT01816815 | Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670 | completed | Phase 1 | 73 | BayerINDUSTRY | 3 | Apr 21, 2014 | clinicaltrials |
| NCT01352208 | Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients | terminated | Phase 1 / Phase 2 | 13 | Astellas Pharma IncINDUSTRY | 3 | Mar 24, 2014 | clinicaltrials |
| NCT01759056 | Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis | completed | Phase 1 | 33 | Avaxia Biologics, IncorporatedINDUSTRY | 4 | Mar 5, 2014 | clinicaltrials |
| NCT01097512 | AS703569 and Gemcitabine Combination in Advanced Malignancies | completed | Phase 1 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Jan 30, 2014 | clinicaltrials |
| NCT01208883 | A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer | completed | Phase 1 | 10 | University Hospital, GhentOTHER | 1 | Jan 24, 2014 | clinicaltrials |
| NCT01527929 | Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | completed | Phase 1 | 25 | SanofiINDUSTRY | 5 | Dec 4, 2013 | clinicaltrials |
| NCT01080664 | A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies | terminated | Phase 1 | 124 | EMD SeronoINDUSTRY | 5 | Oct 22, 2013 | clinicaltrials |
| NCT00028847 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 60 | Commissie Voor Klinisch Toegepast OnderzoekOTHER | 2 | Sep 17, 2013 | clinicaltrials |
| NCT00831636 | A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | Clavis PharmaINDUSTRY | 2 | Sep 13, 2013 | clinicaltrials |
| NCT00785122 | IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)(IMA910-101) | completed | Phase 1 / Phase 2 | 92 | Immatics Biotechnologies GmbHINDUSTRY | 9 | May 16, 2013 | clinicaltrials |
| NCT00698243 | Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 128 | Astellas Pharma IncINDUSTRY | 3 | Apr 15, 2013 | clinicaltrials |
| NCT00560573 | Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 46 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 32 | PfizerINDUSTRY | 6 | Feb 22, 2013 | clinicaltrials |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT01345357 | Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | completed | Phase 1 | 24 | CephalonINDUSTRY | 2 | Jan 18, 2013 | clinicaltrials |
| NCT00372424 | Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | completed | Phase 1 | 26 | PfizerINDUSTRY | 2 | Dec 28, 2012 | clinicaltrials |
| NCT00714649 | Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery(CHIRON) | completed | Phase 1 / Phase 2 | 34 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 14, 2012 | clinicaltrials |
| NCT01280318 | Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery(HNSCC) | completed | Phase 1 / Phase 2 | 60 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 14, 2012 | clinicaltrials |
| NCT01724320 | A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors | unknown | Phase 1 | 20 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 9, 2012 | clinicaltrials |
| NCT01331915 | Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients(THERAVAC) | unknown | Phase 1 / Phase 2 | 23 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00062335 | High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | terminated | Phase 1 | 14 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 24, 2012 | clinicaltrials |
| NCT00128700 | Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00614978 | Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer(LAPTEM) | completed | Phase 1 | 18 | Jules Bordet InstituteOTHER | 1 | Sep 19, 2012 | clinicaltrials |
| NCT00068757 | Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | completed | Phase 1 | 23 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 12, 2012 | clinicaltrials |
| NCT00027677 | Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors | completed | Phase 1 | 25 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Jul 24, 2012 | clinicaltrials |
| NCT00838240 | Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia(AML-14A) | unknown | Phase 1 / Phase 2 | 114 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 20, 2012 | clinicaltrials |
| NCT00788333 | Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer | completed | Phase 1 / Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 13, 2012 | clinicaltrials |
| NCT00003976 | E7070 in Treating Patients With Solid Tumors | completed | Phase 1 | 30 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00003979 | CHS 828 in Treating Patients With Solid Tumors | withdrawn | Phase 1 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials